Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 08:00 ET | Source: Eqrx, Inc.

EQRx to Participate in Cowen’s 42nd Annual Health Care Conference

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
January 18, 2022 19:00 ET | Source: Eqrx, Inc.

Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

Pivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapyOverall survival benefit...
January 18, 2022 08:00 ET | Source: Eqrx, Inc.

EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer

Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung...
January 10, 2022 07:30 ET | Source: Eqrx, Inc.

EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines

The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterpriseIncludes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering...
January 07, 2022 08:00 ET | Source: Eqrx, Inc.

EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs

Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery networkPotential to provide access to affordable treatments in areas of high-cost burden for more...
January 03, 2022 08:00 ET | Source: Eqrx, Inc.

EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at...
December 17, 2021 12:45 ET | Source: Eqrx, Inc.

EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices

Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceedsCombined company to trade on Nasdaq Global Market under ticker “EQRX” NEW YORK and CAMBRIDGE,...